Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + TCb in Triple Negative Breast Cancer
NCT05475678Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- May 2025
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in triple-negative breast cancer (TNBC). Started Dec 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05475678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475678.